The understanding of how hypoxia stabilizes and activates HIF1α in the nucleus with related oncogenic signals could revolutionize targeted therapy for cancers. Here, we find that histone H2AX displays oncogenic activity by serving as a crucial regulator of HIF1α signalling. H2AX interacts with HIF1α to prevent its degradation and nuclear export in order to allow successful VHL-independent HIF1α transcriptional activation. We show that mono-ubiquitylation and phosphorylation of H2AX, which are strictly mediated by hypoxia-induced E3 ligase activity of TRAF6 and ATM, critically regulate HIF1α-driven tumorigenesis. Importantly, TRAF6 and γH2AX are overexpressed in human breast cancer, correlate with activation of HIF1α signalling, and predict metastatic outcome. Thus, TRAF6 and H2AX overexpression and γH2AX-mediated HIF1α enrichment in the nucleus of cancer cells lead to overactivation of HIF1α-driven tumorigenesis, glycolysis and metastasis. Our findings suggest that TRAF6-mediated mono-ubiquitylation and subsequent phosphorylation of H2AX may serve as potential means for cancer diagnosis and therapy.
Hypoxia is a major phenomenon in all solid tumour microenvironments, whereby blood supply and thus oxygen are limited in proliferating cancer cells because of the abnormal tumour microvasculature 1 . Hypoxic cells undergo many stresses including oxidative DNA damage, DNA strand breaks and genetic aberration leading to cell death, whereas cancer cells improve their own genetic index for hypoxic survival and adaptation, thereby acquiring invasive and metastatic capability and resistance to radiotherapy and chemotherapy [2] [3] [4] . Hypoxia-inducible factor 1 alpha (HIF1α) is a primary regulator of the transcriptional response to hypoxia by regulating large numbers of genes involved in glycolysis, cell survival, proliferation, invasion and metastasis [5] [6] [7] [8] [9] . Hence, a better understanding of HIF1α signalling in the hypoxic microenvironment may open the way to efficient targeting of cancer cells.
Ubiquitylation and phosphorylation of protein are shown as important post-translational modifications and play critical roles in diverse biological processes [10] [11] [12] [13] [14] . In normoxic conditions, HIF1α is hydroxylated by prolyl hydroxylase (PHD) and then recognized by Von Hippel-Lindau (VHL) protein, forming an E3 ligase complex to promote HIF1α polyubiquitylation with Ub K48 (at Lys48) and proteasome-dependent degradation 15 . Under hypoxic conditions, HIF1α is stabilized and translocates into the nucleus, where it forms a heterodimer with HIF1β to induce the expression of HIF1α target genes 16 . However, hypoxia-induced stabilization of HIF1α is not sufficient for maintaining the HIF1α level and signalling because VHL-independent proteasome degradation may still occur in certain conditions 17 . It is possible that an unknown key factor in the hypoxic tumour microenvironment protects and enriches HIF1α in the nucleus to activate transcriptional regulation of several oncogenes. Histone variant H2A includes several subfamilies that contain similar conserved amino acid sequences 18, 19 . The H2AX subfamily consists of an additional carboxyl-terminal Ser-Gln-Glu (SQE) motif that C a n c e r t y p e M u t a t io (e) LUC-or H2AX-knockdown MDA-MB-231 cells were treated with vehicle or cisplatin (50 mM) overnight, and cell viability was determined by crystal violet staining and quantified (right panel). n = 3 biological replicate samples. Scale bars, 100 µm. (f) LUC-or H2AX-silenced MDA-MB-231 cells were treated with or without cisplatin, followed by β-galactosidase (β-gal) staining and quantification. n = 3 biological replicate samples. Scale bars, 50 µm. The experiment was performed twice. (g-i) LUC-or H2AX-knockdown MDA-MB-231 cells were synchronized to S phase by thymidine block, and cell samples after release of thymidine block for 24 h under normoxic (g,h) or hypoxic (i) conditions were stained with propidium iodide and analysed by FACS for cell cycle profiles of G0/G1, S, G2/M and polyploidy. n = 3 independent experiments. The quantified results are presented as mean ± s.d. using twotailed t-test (c,h,i) and ANOVA (d-f). * P < 0.05, * * P < 0.01 were considered significant. NS, not significant. See Statistics Source Data in Supplementary  Table 7 .
is highly recognized and phosphorylated by the phosphoinositide 3-kinase-related kinase family, including ataxia-telangiectasia mutated (ATM) 20, 21 . Phosphorylation of H2AX at Ser139 in the SQE motif, known as γH2AX, is a key event in the regulation of homologous recombination repair following ionizing radiation, genotoxic stresses or hypoxia 22, 23 . Surprisingly, γH2AX and monoubiquitylation of H2AX (mUb-H2AX) occur coincidentally [24] [25] [26] , but whether they are induced and crosstalk with each other during hypoxia has not been discovered. Interestingly, histone H2A was shown to be important for transcriptional activation of several genes 27 , but the mechanism behind this is largely unknown. Therefore, we speculated that mUb-H2AX (subfamily of H2A) may regulate γH2AX or vice versa during hypoxia and the localization of HIF1α on DNA wrapped in chromatin with histone proteins such as H2AX might be essential for transcriptional activation of several genes.
H2ax −/− mice display pleiotropic phenotypes, including sensitivity to radiation, immune deficiency and male infertility 28, 29 . Loss of H2AX leads to genomic instability, oncogenic translocation and thymic lymphoma under p53 deficiency, and thus H2AX is considered a tumour suppressor in p53-deficient conditions 30, 31 . However, constitutive H2AX gene mutations are not found in hereditary breast cancer families or in B cell leukaemias or lymphomas 32, 33 . Surprisingly, using three distinct cohorts, we found that copy number and messenger RNA expression of H2AX are amplified in human cancers, correlate with the hypoxia signature and predict poor survival outcome (see the results below), raising the possibility that H2AX overexpression may promote oncogenic activity. Thus, we strived to investigate the role of H2AX in the regulation of HIF1α target genes and cancer progression and metastasis using mouse models and human cancer samples.
H2AX regulates HIF1α signalling, cancer cell glycolysis and tumorigenesis By analysing the oncomine database and a platform of 17,584 tumour samples in The Cancer Genome Atlas (TCGA), we found that the copy number of the H2AX gene was highly amplified in numerous human cancers, such as lung, liver, breast, ovarian, head and neck, stomach and colorectal cancers (Fig. 1a) . Moreover, we used a web database of Gene Expression across Normal and Tumour tissues (GENT) that provides gene expression patterns through more than 34,000 samples. The H2AX gene was highly overexpressed in tumour tissues (Fig. 1b) . Furthermore, inactivation of the H2AX gene disrupted the embryonic growth rate at 17.5 days post coitus (dpc) in normal tissue development (Fig. 1c) , suggesting that H2AX regulates normal cell growth in vivo. Moreover, we found that H2AX loss synergized with cisplatin to elicit cellular senescence and apoptosis ( Fig. 1d-f ). H2AX deficiency could induce cellular senescence in cancer cells, as determined by β-galactosidase (β-gal) staining. However, knockdown of H2AX did not significantly impact on cell cycle progression (Fig. 1g-i) . Thus, H2AX may regulate oncogenic signals independently of cell cycle regulation and its deficiency enhances the sensitivity of cancer cells to chemotherapy.
We next studied a data set representing 255 untreated breast cancer patients registered at The University of Texas MD Anderson Cancer Center. The expression levels of H2AX and HIF1α target gene mRNAs, such as VEGF and PKM2, were significantly correlated ( Supplementary Fig. 1a,b) . Therefore, we investigated whether the expression of H2AX directly regulates HIF1α signalling. Strikingly, the induction of HIF1α target genes was impaired in H2ax −/− mouse embryonic fibroblasts (MEFs) compared with WT MEFs (Fig. 2a) . H2AX knockdown in MCF10A and breast cancer cells also impaired the expression of multiple hypoxia targets in mRNA and protein levels (Fig. 2b-d and Supplementary Fig. 1c) . Conversely, overexpression of H2AX promoted the expression of diverse HIF1α target genes in primary MEFs and breast cancer cells (Fig. 2e,f and Supplementary  Fig. 1d ). Thus, H2AX plays an essential role in HIF1α signalling.
Glucose transporter 1 (GLUT1), as a HIF1α target gene, is a critical mediator of cell survival, proliferation, glucose uptake and aerobic glycolysis in cancer cells 4, 34, 35 . mRNA or protein induction of GLUT1 along with GLUT4 was compromised in multiple H2AX-knockdown cancer cell lines and failure in Glut1 mRNA expression reduced GLUT1 protein presentation on the cell surface under hypoxic conditions ( Fig. 2b-d,g ). H2AX overexpression promotes HIF1α signatures and GLUT1 expression in primary MEFs and cancer cells (Fig. 2e-f and Supplementary Fig. 1d ). H2AX knockdown not only abolished GLUT1 cell surface expression but also reduced glucose uptake and lactate production in cancer cells under hypoxic conditions (Fig. 2g,h and Supplementary Fig. 1e ). We then assessed whether H2AX overexpression could elevate oncogenic processes through HIF1α, which promotes tumorigenesis 3, 34, 36 . Notably, we found that H2AX-overexpressing cancer cells promoted breast tumour growth and volume (Fig. 2i,j) . Interestingly, H2AX-overexpressing cancer cells could promote glucose uptake in hypoxic tumour microenvironments (Fig. 2k,l) . These results point to the critical role of H2AX in glycolysis and breast tumour progression.
To understand whether H2AX regulates HIF1α signalling through its classic role of regulating DNA damage repair, we also examined the role of MDC1 and RNF8; two downstream effectors of H2AX that critically regulate DNA repair, in hypoxic conditions 37, 38 . Unlike H2AX, deficiency and/or silencing of MDC1 or RNF8 in MEFs and breast cancer cells failed to cause any defect in hypoxia signalling ( Supplementary Fig. 1f-j) , suggesting that H2AX-mediated hypoxia signalling is probably not acting through regulating DNA damage signalling and homologous recombination (HR) repair.
H2AX maintains nuclear retention and stability of HIF1α
Hypoxia stabilizes HIF1α and promotes its nuclear translocation 8 . These two events are critical for the induction of HIF1α target genes. Interestingly, we found that HIF1α protein induction during hypoxia in the nucleus of primary MEFs and cancer cells was impaired under H2AX deficiency (Fig. 3a,b and Supplementary Fig. 1k ), and H2AX restoration rescued HIF1α induction in nucleoplasm (Fig. 3c) , which was consistent with our finding that H2AX overexpression could promote HIF1α protein expression in MEFs (Fig. 2f) . Notably, hypoxia enhanced the interaction between HIF1α and H2AX and their co-localization in the nucleus ( Fig. 3d and Supplementary Fig. 1l ). H2AX could bind to nuclear HIF1α in the PAS (Per-ARNT-Sim) and transactivation domains of HIF1α (Fig. 3e) .
We then assessed whether H2AX regulates the stability and nuclear enrichment of HIF1α under hypoxic stimulation. Remarkably, primary H2ax −/− MEFs displayed a defect in HIF1α protein enrichment in the nucleus during hypoxia (Fig. 3f) , and this defect GLUT4 18 F]FDG-glucose incorporation in mice bearing vector-or H2AX-overexpressing breast tumours. Glucose uptake in breast tumours was normalized with muscle tissues in each mouse (n = 6 tumours per group). The quantified results are presented as mean ± s.d. using two-tailed t-test (a,d,e,g,l) and ANOVA (j). * P < 0.05, * * P < 0.01 were considered significant. See Statistics Source Data in Supplementary  Table 7 . Unprocessed original scans of blots are shown in Supplementary  Fig. 9 . HIF1α: was rescued by the proteasome inhibitor MG132 (Fig. 3f,g ). It has been reported that SHARP1 serves as a scaffold to recruit HIF1α to the 20S proteasome for degradation during hypoxia in a VHLindependent manner 17 . Given that the induction of HIF1α during hypoxia is impaired in H2AX -deficient cells, it is highly possible that H2AX prevents the interaction of HIF1α with 20S proteasome under hypoxic stimulation. Indeed, restoration of H2AX in H2AX-knockdown cancer cells inhibited the endogenous interaction between HIF1α and the α4 subunit of the 20S proteasome under hypoxic conditions (Fig. 3h) . Moreover, H2AX deficiency still caused the defect in HIF1α protein induction under hypoxic conditions in the VHLdeficient RCC4 cell line, and this defect could be partially rescued by MG132 treatment (Fig. 3i) . While transient overexpression of H2AX promoted HIF1α induction during hypoxia, SHARP1 overexpression reversed this promoting effect ( Supplementary Fig. 2a) . Conversely, SHARP1 overexpression promoted exogenous HIF1α degradation during hypoxia, and this effect could be partially reversed by H2AX overexpression ( Supplementary Fig. 2b ). Therefore, SHARP1 and H2AX may compete with each other to regulate HIF1α stability during hypoxia. Interestingly, HIF1α was exclusively localized in the nucleus in wild-type MEFs during hypoxia, but was exported into the cytoplasm in H2ax −/− MEFs (Fig. 3f) . Notably, treatment with leptomycin B (LMB), a nuclear export inhibitor, rescued the defect of HIF1α nuclear enrichment in H2ax −/− MEFs during hypoxia (Fig. 3f,j) . Hence, H2AX critically orchestrates the stability and nuclear enrichment of HIF1α by interacting with and preventing HIF1α from binding to 20S proteasome.
TRAF6-mediated mUb-H2AX and γH2AX are essential for HIF1α signalling Whether γH2AX and mUb-H2AX are modulated and there is the functional crosstalk between them during hypoxia remain not well understood. Interestingly, mUb-H2AX and γH2AX were induced by hypoxia in primary MEFs, breast epithelial and/or cancer cells (Figs 2c and 4a and Supplementary Fig. 1c ). To understand which E3 ligase is responsible for mUb-H2AX induction by hypoxia, we performed an in vivo ubiquitylation assay to examine mUb-H2AX formation by screening a panel of E3 ligases. Overexpression of the tumour necrosis factor receptor-associated factor 6 (TRAF6), but none of the others, markedly induced mUb-H2AX ( Supplementary Fig. 3a) . Hypoxia enhanced the formation of mUb-H2AX by TRAF6 ( Supplementary  Fig. 3b ), and TRAF6 could induce mUb-H2AX at Lys119 and Lys120 ( Supplementary Fig. 3c ). Hypoxia facilitated the interaction of γH2AX with HIF1α and TRAF6, and TRAF6 could be detected in the H2AX immuno-complex (Fig. 4b,c and Supplementary Fig. 3d ,e). The E3 ligase activity of TRAF6, auto-ubiquitylation and self-activation were greater in hypoxia than in normoxia for promotion of mUb-H2AX (Fig. 4d,e) . Thus, TRAF6 is probably an E3 ligase for H2AX. To corroborate this finding, we performed an in vitro ubiquitylation assay and found that recombinant TRAF6-WT protein, but not the E3 ligase-dead TRAF6-C70A (TRAF6-CA) mutant, auto-ubiquitylated and induced mUb-H2AX in vitro (Fig. 4f) . Moreover, hypoxia-induced mUb-H2AX was impaired in Traf6 −/− MEFs (Fig. 5d ). Analysis of H2AX amino acid sequences in various species revealed that the ubiquitylation sites (Lys119/120) and phosphorylation site (Ser139) of H2AX are highly conserved across different species ( Supplementary Fig. 3f ). H2AX-WT, but not H2AX-K119R/K120R (H2AX-KR) or H2AX-S139A (H2AX-SA), restoration rescued the defects in the expression of hypoxia targets and notably mUb-H2AX was also required for the induction of γH2AX under hypoxic conditions (Fig. 4g ,h and Supplementary Fig. 5a ). Interestingly, TRAF6-knockdown reduced protein expression of HIF1α targets (Fig. 4i) , whereas overexpression of H2AX-WT, but not H2AX-KR, promoted the expression of GLUT1 localization to the membrane (Fig. 4j,k) . These results suggest that induction of mUb-H2AX by hypoxia mediates the formation of γH2AX, which then plays a crucial role in hypoxia signalling.
Hypoxia-activated TRAF6 constitutes the ATM-γH2AX-HIF1α pathway
We found that E3 ligase activity of TRAF6 under hypoxic conditions is required for promotion of mUb-H2AX (Fig. 4d,e) . Remarkably, TRAF6 could interact and co-localize with endogenous H2AX and was induced by hypoxia, and H2ax −/− MEFs displayed a defect in TRAF6 induction in hypoxic conditions (Figs 4b,c and 5a). Expression of both TRAF6 and HIF1α target genes was also abolished following HIF1α knockdown in various cancer cell lines ( Fig. 5b and Supplementary Fig. 4a ). Moreover, TRAF6 mRNA was induced by hypoxia ( Supplementary Fig. 4b ), suggesting that TRAF6 is a hypoxia-inducible factor and probably a HIF1α target gene. Indeed, the EMSA and CHIP assays revealed that HIF1α could bind to the promoter of TRAF6 ( Supplementary Fig. 4c,d ). Consistently, mRNA expression of TRAF6 in the MD Anderson Cancer Center cohort was significantly correlated with mRNA expression of HIF1α target genes ( Supplementary Fig. 4e ). Therefore, hypoxia drives a feedforward mechanism to further foster mUb-H2AX-mediated HIF1α signalling by inducing Traf6 mRNA expression and subsequent TRAF6 activation.
HIF1α induction was impaired in TRAF6-silenced breast cancer cells and also Traf6 −/− MEFs during hypoxia, and this defect could be rescued by MG132 treatment (Figs 4i and 5c, lower, and Supplementary Fig. 5b ). Consistent with the role of mUb-H2AX in γH2AX formation, Traf6 −/− MEFs also exhibited defects in mUb-H2AX induction and γH2AX formation in hypoxic conditions (Fig. 5d ). Like H2ax −/− MEFs, Traf6 −/− MEFs also displayed impairment of HIF1α target gene expression (Fig. 5d) . A similar induction of mUb-H2AX in hypoxic conditions was seen in MDA-MB-231 cells in which TRAF6 was overexpressed ( Supplementary Fig. 3b ), and restoration of TRAF6, but not TRAF6-C70A, in Traf6 −/− MEFs rescued hypoxia signalling (Fig. 5e) . Thus, the E3 ligase activity of TRAF6 is required for induction of mUb-H2AX, γH2AX formation and HIF1α signalling.
As H2AX interacts with HIF1α to prevent HIF1α degradation and nuclear export, thereby promoting HIF1α signalling, we reasoned that loss of mUb-H2AX or γH2AX may also impair the interaction between H2AX and HIF1α during hypoxia. This was indeed the case, since H2AX-KR and H2AX-SA profoundly lost their ability to interact or co-localize with HIF1α under hypoxic conditions ( Fig. 5f and Supplementary Fig. 5c ). Thus, HIF1α interaction with H2AX during hypoxia is dependent on mUb-H2AX and γH2AX formation.
The ATM-dependent γH2AX formation is crucial for the DNA damage response and HR repair 20, 24 . Unlike γH2AX, which was induced during hypoxia, MRE11 and RNF8 foci were not induced and did not co-localize with γH2AX in the nucleus ( Supplementary  Fig. 2c,d ). Neither MDC1 nor RNF8 deficiency caused any defect in hypoxia signalling ( Supplementary Fig. 1g-j) . Thus, H2AX-mediated hypoxia signalling is distinct from DNA damage signalling. An ATM inhibitor significantly reduced ATM phosphorylation and, γH2AX and HIF1α induction ( Supplementary Fig. 5d ). Consistently, 2) were cultured under normoxia or hypoxia and harvested for chromatin immunoprecipitation (ChIP) with HIF1α antibody followed by qPCR for the expression of VEGF (j) and GLUT1 (k) genes (n = 3, biologically independent extracts). The quantified results are presented as mean ± s.d. of triplicate results using two-tailed t-test. * P < 0.05 was considered significant. See Statistics Source Data in Supplementary Table 7 . Unprocessed original scans of blots are shown in Supplementary Fig. 9 .
overexpression of TRAF6-WT, but not TRAF6-CA, promoted expression of HIF1α targets (Fig. 5g) . Notably, ATM-null cells also displayed defects in γH2AX, HIF1α induction and HIF1α signalling rescued with pBabe-vector, HIF1α-WT or HIF1α-Mut (constitutively active mutant) were injected into the mammary fat pad of nude mice (h,i, n = 4 per group). Tumour sizes were monitored weekly and tumour weight was measured at week 6 (j, n = 4 tumours per group; NS, not significant). Statistical significance was assessed using two-tailed t-test (c-e) and ANOVA (a,g,i,j). Mean ± s.d., * P < 0.05, * * P < 0.01 were considered significant. See Statistics Source Data in Supplementary Table 7 .
Given that mUb-H2AX is required for γH2AX during hypoxia, mUb-H2AX may be critical for H2AX and ATM interaction, thereby regulating γH2AX. Indeed, ATM could bind to H2AX, but not H2AX-KR (Fig. 5i) . Moreover, a ubiquitylated H2AX peptide spanning the region of the H2AX ubiquitylation site (Lys120), but not non-ubiquitylated H2AX peptide, could neutralize the interaction ofmUb-H2AX with ATM and reduced γH2AX formation (Supplementary Fig. 5f ). Restoration of TRAF6, but not TRAF6-C70A, Table 7 . Unprocessed original scans of blots are shown in Supplementary  Fig. 9 .
A R T I C L E S
in Traf6 −/− MEFs rescued the defect in γH2AX formation in chromatin ( Supplementary Fig. 5g ). Since H2AX is required for stability and nuclear enrichment of HIF1α during hypoxia, it is Table 2 ). (c) The expression of TRAF6, H2AX, γH2AX, HIF1α and VEGF significantly predicted disease-specific survival (DSS) and metastasis-free survival (MeFS) as determined by the Cox proportional hazards model and log-rank analysis (see Supplementary  Table 3 ). (d,e) Using multivariate analysis, the combination of TRAF6 with γH2AX/or H2AX, VEGF or GLUT1 and the combination of H2AX/or γH2AX with HIF1α, VEGF or GLUT1 expression demonstrated greater prognostic power for DSS and MeFS. Higher expression of TRAF6 and H2AX in higher grade lesions remained prognostically significant for DSS (TRAF6, P = 0.017; H2AX, P < 0.001) and MeFS (TRAF6, P = 0.042; H2AX, P = 0.045; see also Supplementary Table 4) . (f) A graphical abstract for overactivation of TRAF6-γH2AX-HIF1α signalling under hypoxia. TRAF6 is a hypoxia-inducible gene that is auto-ubiquitylated and self-activated under hypoxia. Active TRAF6 then triggers K 119/120 mono-ubiquitylation of H2AX (mUb-H2AX) for recruitment of activated ATM to H2AX in hypoxic conditions. ATM then drives S 139 phosphorylation of H2AX (γH2AX) for two critical events: (1) on one hand, γH2AX binds to and recruits HIF1α to the promoters of HIF1α target genes for transcriptional activation; (2) on the other hand, γH2AX binds to and stabilizes HIF1α in the nucleus by preventing HIF1α-20S proteasome degradation and also γH2AX inhibits nuclear export of HIF1α through binding to its transactivation domain. Physiologically, overexpression of the H2AX gene, hypoxia-induced TRAF6 activation and upregulation of γH2AX formation along with HIF1α enrichment in the nucleus of cancer cells lead to overactivation of HIF1α signalling, cancer progression and metastasis in the hypoxic tumour microenvironment.
during hypoxia was reduced in two H2AX-knockdown cells (Fig. 5j,k) . Conversely, H2AX, but not H2AX-KR or H2AX-SA, overexpression enhanced the HIF1α level in the VEGF promoter during hypoxia ( Supplementary Fig. 5h ). Thus, TRAF6 mono-ubiquitylates H2AX to drive γH2AX formation by recruiting ATM, leading to regulation of HIF1α signalling.
TRAF6-dependent mUb-H2AX and γH2AX formation promote oncogenic signals
Overexpression and/or restoration of H2AX-WT, but not of vector or H2AX-KR or H2AX-SA, markedly rescued cancer cell survival and proliferation in MDA-MB-231 cancer cells (Fig. 6a,b and Supplementary Fig. 6a ). H2AX-WT, but not H2AX-KR or H2AX-SA, significantly promotes the wound healing and migration capability of MDA-MB-231 cells (Fig. 6c and Supplementary Fig. 6b ). Remarkably, restoration of H2AX-WT, but not H2AX-KR or SA, in H2AX-deficient cancer cells, significantly reconstituted breast tumour growth and weight compared with restoration of H2AX-KR or -SA or vector control (Fig. 6d,e) . H2AX therefore promotes cancer cell proliferation, migration and breast tumour progression in a manner dependent on mUb-H2AX and γH2AX.
Consistently, TRAF6, but not TRAF6-CA, overexpression markedly promoted cancer cell migration and invasion in vitro and breast tumour growth in vivo (Fig. 6f,g ). Thus, E3 ligase activity of TRAF6 is important for breast cancer development. To understand whether the TRAF6-H2AX axis regulates breast cancer progression acting through HIF1α signalling, we rescued TRAF6-and H2AX-deficient breast cancer cells with HIF1α-WT and/or constitutively active HIF1α-mutant (-Mut). Remarkably, restoration of HIF1α-Mut in TRAF6-and H2AX-deficient cancer cells significantly reconstituted breast tumour growth and weight in vivo compared with restoration of vector control (Fig. 6h-j and Supplementary Figs 6c and 8a-c) . Hence, the TRAF6-H2AX axis promotes breast cancer development via HIF1α regulation.
TRAF6 and H2AX are potential targets for eradication of metastatic tumour
H2AX knockdown in breast cancer cells impaired mRNA or protein induction of VEGF, iNOS and ANG genes (Fig. 2b,c) . Consistently, the level of secreted VEGF protein was dramatically reduced in the conditioned medium from H2AX-knockdown cancer cells ( Supplementary Fig. 6d ), implying that H2AX may play a role in angiogenesis of cancer cells. We next examined the role of H2AX targeting in breast cancer migration, invasion and metastasis. H2AX knockdown in cancer cells impaired migration and invasion in vitro ( Supplementary Fig. 6e,f) . Remarkably, H2AX deficiency in triple-negative breast cancer cells significantly reduced breast tumour volume (P < 0.05 at week 6) (Fig. 7a) . Immunohistochemical analysis revealed that H2AX knockdown downregulated VEGF in breast tumour tissue and VEGF-driven angiogenesis, correlated with tumour suppression (Fig. 7b) . H2AX knockdown downregulated the proliferation marker Ki-67 in breast tumour tissue but induced active caspase-3 (P = 0.0042; Fig. 7b ). H2AX targeting sensitized cancer cells to cisplatin-induced apoptosis and senescence (Fig. 1e,f) . Notably, H2AX-WT, but not vector or H2AX-KR or H2AX-SA, markedly rescued cancer cell survival and proliferation in MDA-MB-231 cells (Fig. 6a,b and Supplementary Fig. 6a ). Treatment of ubiquitylated H2AX peptide, but not of non-ubiquitylated H2AX, led to early apoptosis of cancer cells (Supplementary Fig. 6g ). Thus, H2AX and/or mUb-H2AX targeting deactivates survival, angiogenesis and metastasis of cancer cells.
To examine the role of TRAF6 or H2AX targeting in breast cancer progression and metastasis, we inoculated H2AX-WT or H2AX-deficient MDA-MB-231 cancer cells into the tail vein of nude mice. H2AX deficiency in MDA-MB-231 cells prolonged mouse survival (P = 0.0127) and attenuated breast cancer metastasis to lung and liver (Fig. 7c,d) . Inoculation of TRAF6-overexpressing breast cancer cells into the tail vein of mice attenuated mouse survival (P = 0.0039) and promoted breast cancer metastasis to lung and spinal bone (Fig. 7e-g ). Unlike vector (pMX)-driven lung metastasis, promotion of TRAF6-driven breast cancer cells to spinal bone was confirmed by micro computed tomography (microCT) using the Biospec 7T MRI system, indicating that overexpression of TRAF6 has more unique functions in the bone metastasis. Thus, TRAF6 and H2AX serve as important regulators in tumour metastasis.
It was discovered that TRAF6 is a respective target of the microRNA miR-145 39 . We confirmed that overexpression of miR-145 reduces TRAF6 expression in cancer cells 40 . Thus, we assumed that targeting of TRAF6-driven tumorigenesis by miR-145 may eradicate cancer progression and metastasis. Indeed, miR-145 overexpression reduced breast tumour growth (Supplementary Fig. 8d ). Remarkably, miRNA targeting of TRAF6 in MDA-MB231 cells injected into the lateral tail vein of mice significantly reduced the percentage of poor survival (P = 0.0255, Fig. 7h,i) . Although breast metastasis to spinal bone was enriched at a later time with our unique control (MSCV)-silenced cancer cells (in 4 out of 5 mice), it was profoundly inhibited by miR-145, correlated with metastatic suppression (Fig. 7h) , indicating that miRNA targeting of TRAF6 in cancer cells increased the overall survival of mice and opens up opportunities for therapeutic intervention.
γH2AX-mediated HIF1α activation predicts metastatic outcome in breast cancer patients
Using bioinformatics analyses, TRAF6 upregulation in breast cancer was associated with aberrant elevation of cancer hallmarks and oncogenic transformation ( Supplementary Fig. 7a-d) . Using cBioPortal web-based data sets (http://www.cBioPortal.org) and Ingenuity Pathway Analysis (IPA) (http://www.ingenuity.com), the TRAF6, H2AX and HIF1α network exists significantly with cooccurring alterations in many cancer types ( Supplementary Fig. 8e,f) . Immunohistochemical analysis of the in-house Taiwanese cohort of 212 human breast carcinomas revealed that HIF1α, H2AX, γH2AX, VEGF and GLUT1 proteins were all highly co-expressed and their overexpression significantly associated with increments of primary tumour status (pT, P ≤ 0.002), nodal metastasis (pN, P ≤ 0.002), and stage (P ≤ 0.006) (Fig. 8a and Supplementary Table 1) . TRAF6, H2AX, γH2AX, HIF1α and VEGF were expressed at low to moderate levels in early-stage breast carcinomas and significantly overexpressed in later-stage lesions. TRAF6, H2AX and γH2AX positively correlated with hypoxia signatures and predicted disease-specific survival (DSS) and metastasis-free survival (MeFS) as determined by the Cox proportional hazards model and log-rank analysis (Fig. 8b,c and Supplementary Tables 2 and 3 ). In the multivariate analysis, TRAF6 and H2AX overexpression in higher-grade tumours remained prognostically significant for DSS (TRAF6, P = 0.017; H2AX, P < 0.001) and MeFS (TRAF6, P = 0.042; H2AX, P = 0.045) (Supplementary Table 4) . Interestingly, the combinations of TRAF6 with H2AX, γH2AX, HIF1α, VEGF and GLUT1 expression; H2AX with HIF1α, VEGF and GLUT1 expression; and γH2AX with HIF1α, VEGF and GLUT1 expression demonstrated great prognostic power for DSS and MeFS (Fig. 8d,e and Supplementary Table 4) . Thus, the TRAF6, H2AX and γH2AX network is correlated with HIF1α signalling and predicts poor survival outcome in human breast cancer patients.
DISCUSSION
H2AX is proposed to serve as a dose-dependent suppressor of genomic instability in lymphomas in p53-deficient conditions 30, 31 . However, in the TCGA and GENT, we found that the copy number of the H2AX gene and mRNA were highly amplified in numerous human cancers. Remarkably, mRNA expression of TRAF6, H2AX and HIF1α target genes is significantly correlated and their proteins along with γH2AX were overexpressed in the hypoxic tumour microenvironment from the study of the TCGA, MD Anderson Cancer Center and Taiwanese cohorts. Interestingly, cells lacking H2AX display a significant defect in expression of HIF1α target genes (Fig. 2a-d) . H2AX overexpression correlates with activation of HIF1α signalling and serves as a marker for poor prognosis in breast cancer patients and such correlation predicts DSS and MeFS. We demonstrated that H2AX promotes HIF1α-dependent cancer progression and metastasis by regulating multiple biological processes, including glycolysis, cell proliferation, cellular senescence, cell migration and invasion. Hence, H2AX plays an important role in a hypoxic tumour microenvironment to promote tumour phenotypes.
How HIF1α is stabilized and enriched in the nucleus in a VHLindependent manner during hypoxia remains largely unknown. We identify H2AX as a key player for maintaining the stability and nuclear enrichment of HIF1α in the nucleus under hypoxic conditions. Mechanistically, H2AX interacts with HIF1α and helps prevent the interaction of HIF1α with α4 proteasome, thereby facilitating HIF1α stability and nuclear enrichment in hypoxic conditions in a VHLindependent manner. These findings constitute a significant advance in our knowledge of how hypoxia regulates nuclear enrichment and/or stabilization of HIF1α to drive numerous oncogenic functions. Thus, our study provides important insights into the crucial role of H2AX in HIF1α-driven tumorigenesis via stabilization and activation of HIF1α signalling.
TRAF6 is activated by several cellular stimuli, including ionizing radiation, cytokines and growth factors [41] [42] [43] . However, how TRAF6 activation is regulated by physiological stimuli in hypoxic tumour microenvironments remains largely unknown. We identify that TRAF6 is auto-ubiquitylated and activated during hypoxia to drive mUb-H2AX at Lys119/120, thereby regulating γH2AX formation and induction of HIF1α target genes. Notably, TRAF6-driven mUb-H2AX is a prerequisite for recruiting ATM to drive γH2AX formation for transcriptional activation during hypoxia. We show that TRAF6 is a hypoxia target whose activation by hypoxic tumour microenvironments can provide a feedforward mechanism to further amplify HIF1α signalling by inducing TRAF6 mRNA expression and subsequent auto-ubiquitylation and activation. TRAF6 overexpression promotes breast cancer progression and metastasis to lung and spinal bone, and targeting of TRAF6 by miR-145 reduces breast cancer metastasis, opening up opportunities for therapeutic intervention. E3 ligase activity of TRAF6 along with mUb-H2AX and γH2AX formation promotes oncogenic signals and these modifications are required for H2AX-mediated breast cancer progression. Our study expands the known roles of γH2AX to include not only DNA damage repair but also hypoxia signalling (Fig. 8f) . Thus, pharmacological targeting of TRAF6, mUb-H2AX and γH2AX formation may be an effective strategy for hypoxia-and HIF1α-driven cancers.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3445
Patients and human tissues. The cohort of breast cancer patients registered at MD Anderson Cancer Center includes 225 patients with stage I to III breast cancer who had not received any treatment before sample collection. Breast tumour biopsies of this cohort were collected by fine-needle aspiration, with minimal contamination of normal tissues. The mRNA expression of H2AX, TRAF6 and other genes was quantified using the microarray analysis platform from Affymetrix ((HG-U133A) Affymetrix Human Genome U133A Array). Expression analysis was carried out by Nexus Expression 0.3 software (Biodiscovery). Immunoexpression of the Taiwanese cohort was assessed on 212 consecutively treated patients with primary breast carcinoma who underwent modified radical mastectomy between 1997 and 2002 at Chi-Mei Foundational Medical Center. None of these patients received adjuvant chemotherapy. Pathological staging was based on the system defined by the American Joint Committee on Cancer 7th edition. In this study, the institutional review board of Chi-Mei Medical Center granted the research use of formalin-fixed materials with consent to participate in anonymous processing for research purposes that would preclude the identification of personal information of the participants (9812012).
Cell cultures and reagents. Primary mouse embryonic fibroblasts (MEFs) from wild-type (WT), H2ax −/− and Traf6 −/− mice were prepared as described previously 31, 41, 44 . MEF, MDA-MB-231, MCF7, BT474, A549, U2OS, RCC4 and 293T cells were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS). None of these cell lines is found in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. All cell lines were obtained from American Type Culture Collection (ATCC), and they were confirmed to be mycoplasma negative before experiments. The cell lines were not authenticated. The pcDNA3-HA-FLAG-H2AX-K74/75R, pcDNA3-HA-FLAG-H2AX-K119R/K120R and pcDNA3-HA-FLAG-H2AX-K134/135R constructs were generated by using a site-directed mutagenesis kit (Stratagene) according to the manufacturer's standard procedures with pcDNA3-HA-FLAG-H2AX-wild type (WT) as a template. The pWZL-H2AX-WT, pWZL-H2AX-K119R/K120R and pWZL-H2AX-S139A constructs were generated by subcloning H2AX, H2AX-K119R/K120R or H2AX-S139A into the EcoRI and BamHI sites of the pWZL vector. The construction of Flag-TRAF6-WT, Flag-TRAF6-C70A, pGEX-4X1-TRAF6 and pGEX-4X1-TRAF6-C70A was described previously 41, 45 . pMX-TRAF6 was obtained from B. G. Darnay (The University of Texas MD Anderson Cancer Center, USA). pcDNA3-HA-FLAG-H2AX-WT and pcDNA3-HA-FLAG-H2AX-S139A were a gift from J. Chen. pBabe-vector, pBabe-HIF1α and pBabe-HIF1α-Mut were purchased from Addgene. (His) 6 -ubiquitin was a gift from D. Bohmann and (His) 6 -ubiquitin K48R and (His)6-ubiquitin K63R were a gift from M. Eilers. Flag-Smurf2 and Flag-FBW7 were obtained from J. L. Wrana and M. H. Lee (The University of Texas MD Anderson Cancer Center, USA), respectively. Flag-c-IAP1 and Flag-c-IAP2 were obtained from X. Yang. Flag-HIF1α truncates (1-330, 331-698 and 699-826) were received from J. Cheng. HA-SHARP1 was a kind gift from S. Piccolo. MDC1 and RNF8 shRNAs were obtained from Z. Lou. H2AX and SHARP1 siRNAs were purchased from Dharmacon. Cell transfection was performed using Lipofectamine 3000 (Invitrogen) and DharmaFECT Transfection Reagents following the manufacturer's protocol. The non-ubiquitylated (CVLLPKKTSAT) and ubiquitylated H2AX (CVLLPK(ub-K)TSAT) peptides were generated by Millipore. ATM inhibitor KU55933 was purchased from Calbiochem. Leptomycin B and 2-NBDG were received from Sigma. MG132 was purchased from Cayman Chemical. Cisplatin was received from ALEXIS Biochemicals.
Viral infection for silencing, restoration and overexpression. Lentiviral shRNAs of H2AX, HIF1α, TRAF6 and luciferase (control) were used and each shRNA was co-transfected with packing ( VPR8.9) and envelope (VSV-G) plasmids into 293T cells using Lipofectamine 2000 reagent according to the manufacturer's standard procedures. Virus particles containing H2AX, HIF1α, TRAF6 or luciferase shRNA(s) were used to silence these genes in mammalian cells. Retroviral plasmids were transfected into Phoenix packing cells. Transfected cells were cultured for 2 days and the virus-containing medium was harvested and used for restoration or overexpression of these proteins in the target cells. All of the infected cells were selected in the medium with appropriate antibiotics for 4 days to be stable according to a previously published protocol 25 . Sequences of shRNAs are listed in Supplementary Table 5 .
Quantitative polymerase chain reaction with reverse transcription. Total RNA was extracted and treated with DNase by using the RNeasy Mini Kit (QIAGEN) according to the manufacturer's recommendations. Purified RNA was reversetranscribed with oligo dT using the Superscript II Kit (Invitrogen). Control of genomic contamination was measured for each sample with or without reverse transcriptase. Real-time PCR was performed with the SYBR Green PCR Master Mix Kit (Applied Biosystems). Relative quantitative RNA was normalized to the housekeeping genes β-actin and 18S rRNA with the C t method. The entire procedure was repeated in three biologically independent samples. Error bars represent the standard deviation (s.d.) of the mean. The list of primers is presented in Supplementary Table 5 .
Chromatin immunoprecipitation. The ChIP assay was performed with a chromatin immunoprecipitation kit in accordance with the manufacturer's instructions (Upstate Biotechnology). Chromatin was precipitated with anti-HIF1α (ab2185, Abcam) and anti-γH2AX (2577, Cell Signaling Technology) antibodies. GAPDH antibody (Upstate Biotechnology) was used as a positive control. Promoter binding was quantified by real-time PCR. The regions of the referenced human VEGF and GLUT1 gene promoters were amplified with the primer pairs listed in Supplementary Table 5 .
Electrophoretic mobility shift assay (EMSA). The Thermoscientific Biotin 3 End DNA Labeling Kit was used according to the manufacturer's recommendations. The EMSA was carried out using the Thermo Scientific Pierce Chemiluminescent Nucleic Acid Detection Module for detection of biotin-labelled nucleic acid probes in membrane blotting. Sequences of probes are listed in Supplementary Table 5 .
Immunoprecipitation (IP), immunoblotting (IB), immunofluorescence (IF) and immunohistochemistry (IHC)
. IP, IB, IF and IHC assays were performed as described previously, with brief modifications 46 . For protein-protein interactions (IP), cells were subjected to lysis by E1A lysis buffer (250 mM NaCl, 50 mM HEPES (pH 7.5), 0.1% NP-40, 5 mM EDTA, protease inhibitor cocktail (Roche)). For IF, cells were grown on chamber slides. After incubation in normoxic or hypoxic (1% oxygen) conditions for 12 h, cells were washed and fixed with 4% paraformaldehyde and subjected to permeabilization in 0.3% Triton X-100 and 5% glycine in phosphate-buffered saline solution (PBS) on ice. Cells were blocked in 4% bovine serum albumin (BSA) and immunolabelled with specific antibodies, and then observed by Zeiss Cell Observer imaging and Zeiss 710 confocal microscopy. The list of the main commercial antibodies with catalogue numbers, applications and dilutions is included in Supplementary Table 6 . The anti-SHARP1 antibody was a gift from S. Piccolo (IB: 1:1,000). Each image resulting from western blots and immunofluorescence is representative of at least three independent experiments. Ubiquitylation assay. In vitro and in vivo ubiquitylation assays were performed as described previously 41 . In brief, 293T cells were transfected with the indicated plasmids for 48 h and harvested by denatured buffer (6 M guanidine-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 10 mM imidazole), subjected to nickel bead purification for 3 h, washed and subjected to western blot analysis. For the in vitro ubiquitylation assay, recombinant wild-type or mutant GST-TRAF6 and GST-H2AX were purified from the bacterial lysates of BL21-competent cells and then incubated for 3 h at 37 • C in 20 µl of reaction buffer (20 mM Hepes (pH 7.4), 10 mM MgCl 2 , 1 mM dithiothreitol (DTT), 59 µM ubiquitin, 50 nM E1, 850 nM of Ubc13/UeV1a, 1 mM ATP, 30 µM creatine phosphate, and 1 U of creatine kinase). After incubation, protein mixtures were diluted in RIPA buffer and the supernatant fluid was precleared with Protein A/G beads for 1 h and immunoprecipitated overnight with 1 µg anti-Flag antibody, after which Protein A/G beads were added for an additional 1 h. The beads were washed four times with E1A buffer. Proteins were eluted in sodium dodecyl sulfate (SDS) sample buffer and subjected to polyacrylamide electrophoresis on a 12% gel, transferred to a nitrocellulose membrane and immunoblotted with antibody.
Nucleoplasm and chromatin fractionations. Cytoplasmic and nuclear fractions were collected according to the recommended procedure with an Active Motif extract kit, and chromatin fractionation was performed as described previously 47 . In brief, cells were treated under normoxic or hypoxic (1% oxygen) conditions and washed twice with cold PBS. Cell pellets were resuspended in buffer A (50 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 10% glycerol, 1 mM DTT, protease inhibitor cocktail (Roche), 0.1% Triton X-100 and phosphatase inhibitor cocktail I and II (Sigma)) on ice. After centrifugation, pellets were subjected to lysis by buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease inhibitor cocktail and phosphatase inhibitor cocktail I and II). After a second centrifugation, pellets were washed twice with washing buffer I (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 150 mM NaCl, protease inhibitor cocktail) and buffer II (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 250 mM NaCl, protease inhibitor cocktail). After washing, pellets were subjected to sonication and lysis by E1A lysis buffer. Then proteins were analysed by IB. from each shRNA were pooled and used for cell growth, colony formation, and senescence assays after western blot validation. For the cell growth assay, 2 × 10 4 cells were seeded in 12 wells in triplicate, harvested, and stained with trypan blue on different days; numbers of viable cells were directly counted under the microscope. In parallel, the same numbers of cells were cultured for MTT proliferation assay according to the standard protocol, and chromogenic concentration indicating the cell number per day was measured using standard microplate absorbance readers (570 nm). For assessment of colony formation, 1 × 10 3 cells were seeded in 6-well plates for 10 days and later stained with Gram stain kit (ENG Scientific). To determine cellular senescence, MDA-MB-231 cells were plated at 10 4 cells per well of a 6-well plate in triplicate with or without 50 mM cisplatin and, after 4 days, SA-β-gal activity was measured by using the senescence detection kit (Calbiochem) and quantified (around 100-200 cells per well). The number of cells per well with SA-β-gal activity induced by cisplatin was normalized by the percentage of the total control and knockdown cells.
Enzyme-linked immunosorbent assay (ELISA).
H2AX-knockdown and control MDA-MB-231 cells were cultured in 60-mm 2 dishes in triplicate under normoxic and hypoxic (1% oxygen) conditions for 24 h. Cell culture supernatants were collected by centrifugation at 1,500 r.p.m. (164g ). VEGF concentration was determined in duplicate for each sample using the Quantikine human VEGF ELISA Kit (R&D Systems) following the manufacturer's recommended method. The concentration was calculated by linear regression from a standard curve.
Cell migration, invasion and wound healing assays. The cell migration and invasion assays were performed in a 24-well Transwell plate with 8-µm polyethylene terephthalate membrane filters (Falcon cell culture insert; Becton-Dickinson) separating the lower and upper culture chambers. In brief, MDA-MB-231 or A549 cells in which H2AX had been knocked down and restored were plated in the upper chamber at 10 5 cells per well in serum-free DMEM, while the bottom chamber contained DMEM with 10% FBS. Cells were allowed to migrate for 6 h. Cells that migrated to the lower surface of the filter were fixed with 4% (w/v) paraformaldehyde and stained with 0.5% (w/v) crystal violet. Cells were counted in three random fields by Zeiss Cell Observer imaging. The invasion assay of MDA-MB-231 cells was essentially similar to the cell migration assay, except that the membrane filter was precoated with diluted Matrigel (Matrigel/serum-free DMEM, 1:3) before the assay and the incubation time was 16 h. For the wound healing assay, MDA-MB-231 cells in which H2AX was knocked down and then rescued with wild-type or mutant H2AX were seeded overnight in 12-well plates in triplicate. Confluent cells were subjected to an in vitro scratch, and wound healing was recorded by Zeiss 710 confocal microscopy.
Lactate production assay. Control or H2AX-knockdown MDA-MB-231 cells were plated in 12-well dishes and cultured overnight. Next, cells were incubated in normoxic or hypoxic (1% oxygen) conditions for 24 h. The culture medium was removed from the cells and the lactate concentration was determined by using lactate test strips and an Accutrend Lactate analyser (Roche). Next, cells were harvested and viable cells were counted; the rate of lactate production was normalized to the rate detected in the control group.
Flow cytometric analysis of cell surface GLUT1 expression, cell cycle profiling and apoptosis. MDA-MB-231 cancer cells were incubated in normoxic or hypoxic conditions for 12 h. The cells were fixed with cold 1% paraformaldehyde, blocked in 4% BSA and stained with anti-GLUT1 antibody in PBS including 0.3% Triton X-100 and 5% glycine for 2 h at 22 • C. The secondary antibody was fluorescein isothiocyanate-conjugated goat anti-mouse incubated for 30 min at 22 • C. Cells were suspended in PBS to be analysed using a fluorescence-activated cell sorting FACScaliber flow cytometer. Data were analysed and plotted by using Flow Jo version 7.5.5 software. For cell cycle profiling, MDA-MB-231 cells were synchronized to S phase by thymidine block for 24 h and then released under normoxic conditions. Cell samples were stained with propidium iodide and analysed by FACS for profiles of G0/G1, S, G2/M and polyploidy. Annexin V-FITC apoptosis detection kit (BD Biosciences) was used for detection of early cell apoptosis according to the manufacturer's instructions.
In vivo and in vitro glucose uptake assay. Stable MDA-MB-231 cells silenced with luciferase or H2AX lentiviral shRNA were seeded in 60-mm plates overnight. The next day, cells were refreshed with serum-starved (0.1% FBS) and glucosefree DMEM under normoxic and hypoxic (1% oxygen) conditions for 24 h, in the presence of the fluorescent glucose analogue 2-NBDG (50 mM; Invitrogen) for 2 h. The 2-NBDG uptake ratio by cells was quantified by using FACS analysis. For in vivo glucose uptake, vector-or H2AX-overexpressing MDA-MB-231 cells were injected into the mammary fat pad of female nude mice (n = 4 per group, 6 week old). When the volume of the tumours reached ∼200 mm 3 , a single tailvein injection of [
18 F]FDG was administered to the mice and then PET/CT images were scanned and collected on an Inveon CT/PET system (Siemens). Mice were then awake during the uptake period and maintained on a heating pad. Images were reconstructed by a two-dimensional ordered subset expectation maximization (OSEM) algorithm. PET and CT image fusion and image analysis were performed using ASIPro 5.2.4.0 software (Siemens).
In vivo tumorigenesis and metastasis assays. Stable MDA-MB-231 cells (3 × 10 6 ) silenced with luciferase or H2AX lentiviral shRNA were mixed with Matrigel (1:1) and inoculated in the mammary fat pad of immunodeficient female nude mice (n = 4 per group, 6 week old). Stable MDA-MB-231 cells with H2AX knockdown were rescued by H2AX-WT, H2AX-KR, H2AX-SA or mock and were injected subcutaneously into the right flank of 6-week-old athymic female nude mice (n = 5 per group). Tumour sizes of mice were measured weekly with a calliper, and tumour volume was determined with the following standard formula: L×W 2 × 0.52, where L is the longest diameter and W is the shortest diameter. Tumour weight was measured in the final week. For in vivo metastasis assay, stable MDA-MB-231 cells (2 × 10 6 ) silenced with luciferase or H2AX lentiviral shRNA were injected into the lateral tail vein of athymic female nude mice (6 week old). After 12 weeks, mice (n = 5 per group) were killed and the lung, liver and spleen tissues were analysed for the occurrence of metastasis using IHC staining. All animal experiments were carried out in accordance with the regulations of the American Association for Laboratory Animal Science and the approval of The University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee (IACUC).
Statistics and reproducibility.
Clinical statistical analyses were performed by using the SPSS 14 software package. The Kruskal-Wallis H test and Mann-Whitney U test were used to assess the differential expression levels of TRAF6, H2AX, γH2AX, HIF1α, VEGF and GLUT1 in relation to important clinicopathologic variables. The Pearson correlation coefficient was used to clarify the association between TRAF6, H2AX, γH2AX, HIF1α, VEGF and GLUT1 expression levels. The endpoints analysed were disease-specific survival (DSS) and distal metastasis-free survival (MeFS), defined as the interval from the date of surgery to the date of diseaserelated death or metastatic event. The median period of follow-up duration was 103.7 months (range, 6 to 144). Univariate survival analysis was performed by using the Cox proportional hazards model. Survival curves were plotted by using the Kaplan-Meier method. A multivariate survival analysis was performed by using Cox proportional hazards regression, including parameters with univariate P < 0.05. Since primary tumour status (pT) and nodal status (pN) are component factors of tumour stage, only stage was rolled into multivariate analysis. No samples or animals were excluded from the analysis. No statistical method was used to predetermine sample size and experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. In vitro experimental data are presented as means ± s.d. of three independent results, n refers to biological replicates and statistical significance was assessed by the two-tailed paired Student t-test and/or ANOVA. * P < 0.05 and * * P < 0.01 were considered significant. Figures 2c,k, Data availability. The breast cancer patient data set GSE20194 was downloaded from the Gene Expression Omnibus database. This cohort was analysed with Nexus Expression 3.0 (BioDiscovery) and a Circos map building tool (Circos software, www.circos.ca). The amplification and expression of H2AX were assessed using data sets of The Cancer Genome Atlas (TCGA) (http://www.cBioPortal.org) and GENT (http://medicalgenome.kribb.re.kr) with the accession number GSE2109. Source data for Fig. 8a Supplementary Fig. 9 . Supplementary Figure 4 TRAF6, a hypoxia responsive gene, regulates HIF1α signalling. a, MDA-MB-231 cancer cells in which Luc or HIF1α was silenced by shRNA were cultured in normoxic or hypoxic conditions for 8 h, and lysates were collected for IB analysis. b, Primary MEF cells cultured in hypoxic conditions for 2 and 4 h were subjected to qPCR of Traf6 mRNA (n=3, biologically independent extracts).. c, Lysates of HEK-293 cells were treated with biotin-labeled TRAF6-DNA or along with biotin-labeled TRAF6-DNA and cold DNA (not Labeled) compared to labeled-DNA alone were subjected to electrophoretic mobility shift assay (EMSA). d, Hela cells were cultured in normoxic or hypoxic conditions and harvested for chromatin immunoprecipitation (ChIP) with HIF1α antibody followed by qPCR for the expression of TRAF6 genes and were compared to GAPDH control. e, Scatter plots were generated for the correlated expression of HIF1α target genes with TRAF6. Tumour tissues were used from 255 untreated patients with stage 1-3 breast cancer. The biopsies were obtained through fine-needle aspiration. Expression analysis was carried out by Nexus Expression 0.3 software (Biodiscovery). f, g, LUC or TRAF6 knockdown MDA-MB-231 cells were subjected to cell cycle analysis (n=3, independent experiments). Statistical significance of three biological replications was assessed by two tailed t test. Mean ± SD, p<0.01 was considered significant. Unprocessed original scans of blots are shown in Supplementary  Fig. 9 . Supplementary Figure 6 H2AX-targeting reduces cancer cell survival, migration and tumourigenesis. a, MDA-MB-231 cells stably overexpressing vector, H2AX-WT or H2AX-KR or -SA mutant were harvested for cell viability assay (n=3, biological replicate samples). b, H2AX knockdown MDA-MB-231 cells rescued with H2AX-WT or an H2AX mutant were seeded in triplicate for a wound healing analysis using confocal microscopy. c, Luciferase expressing MDA-MB-231 cancer cells in which H2AX was silenced by shRNA and then restored with vector, HIF1α-WT or HIF1α-Mut were injected into the mammary fat pad of nude mice and luciferase expression in tumour growth was counted. d, Luc or H2AX knockdown MDA-MB-231 breast cancer cells were cultured in normoxic or hypoxic conditions for 24 h, and the conditioned media were collected for detection of secreted VEGF by ELISA assay (n=4, biological replicate samples). e-f, MDA-MB-231 cells in which Luc or H2AX was silenced with two different shRNAs and plated in transwell chambers for the cell migration (e) and invasion (f) assay (n=4, biological replicate samples). Scale bar=100 µm. g, MDA-MB-231 cells were treated with non-ubiquitinated (left, CVLLPKKTSAT) and ubiquiitnated H2AX (right, CVLLPK(ub-K) TSAT) peptides (10 ng/ml) overnight, and cell viability was determined by flow cytometry. Statistical significance was measured using two tailed t-test (e-f) and ANOVA (a, d). Mean ± SD, **P<0.01 and *P<0.05 were considered significant. types of mutation which is involved in functional effect, inheritance mode, translation impact, unclassified mutation, zygosity and wild type were analysed using Ingenuity Pathway (http://www.ingenuity.com/). The publication data range was from Jan. 1954-Apr. 2016. f, Activation of TRAF6, H2AX and HIF1α network in cancer genomics was proven by cBioPortal web-based data sets (http://www.cbioportal.org)1,2. Panels e and f indicate that this network is significantly existed including TRAF6, H2AX and HIF1α gene pairs with co-occurring alterations in many cancer types. Statistical significance was assessed by ANOVA. Mean ± SD. ns, not significant. P<0.01 was considered significant. 
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